Cycle on Jul 20, 2026

I will begin by listing the open threads of interest for this research topic. This will help identify any targeted questions, active watches, or unresolved issues from prior cycles that need attention.

I will search for recent news regarding Capricor's deramiocel (BLA for Duchenne muscular dystrophy cardiomyopathy), Replimune's RP1 (melanoma), and any general high-stakes regulatory or clinical updates from the past week.

I will expand my search query to find recent clinical, regulatory, space, or public health news, using terms related to some of the active watches scheduled for July 2026. Let's search for "Capricor deramiocel", "Replimune RP1", "Saol SL1009", "Amgen Tavneos", "H5N1 bird flu New Zealand", or general biotech news from the last week. Let's do a broader search with fewer keywords or less restrictive terms. I'll search for "Capricor deramiocel" first without sorting by recent if needed, or with freshness "month" to see what has happened since the last cycle. Let's start with freshness "month" for "Capricor" and "Replimune" to see if there are updates on their advisory committees. Let's also search for "H5N1" and "bird flu" in Australia/New Zealand.

Ah! On June 26, 2026, Capricor announced that the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) is scheduled for July 29, 2026, and the PDUFA target action date is August 22, 2026. Let's search for "Replimune RP1 FDA advisory committee" to see if there is any update on Replimune's adcom date, which was scheduled for "late July 2026" with a PDUFA date of August 2, 2026. Let's run a search.

Let's check if the FDA's advisory committee calendar lists the specific date for the Replimune RP1 adcom, or if there are other oncology adcoms scheduled for late July 2026. I'll search for "Oncologic Drugs Advisory Committee" or "Replimune" or "vusolimogene oderparepvec" on FDA's advisory committee calendar. Let's run a search.

Ah, the Old Dominion Athletic Conference is also called ODAC. Let's filter out sports with `-sports` or `-basketball` or `-Guilford` or `-Athletic` or `-swimodac` and focus on the FDA. Let's search for `Replimune ODAC July 2026` or `Replimune "Oncologic Drugs Advisory Committee" July 2026`. Or let's just search for `"Oncologic Drugs Advisory Committee" meeting "July" 2026` to see what days are scheduled. Let's do a search.

Wait! In the second search result, the snippet says: "... July 30, 2026 Meeting Announcement- UPDATED ...". This suggests there is an Oncologic Drugs Advisory Committee meeting scheduled for July 30, 2026! Let's search for "July 30, 2026" "Oncologic Drugs Advisory Committee" or "July 30, 2026 Meeting Announcement" to see if this is indeed the Replimune RP1 adcom meeting or if it's another product. Let's do a search.

Excellent! Let's read the Federal Register notice or the FDA calendar page for both Capricor and Replimune. Wait, let's fetch the page for Capricor's adcomm first, then Replimune's adcomm. Wait! Let's look at the first URL in the Capricor search: `https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-july-29-2026-meeting-announcement-07292026` And the Replimune search: `https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-july-30-2026-meeting-announcement-07302026` Notice that both of these are Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meetings, not ODAC! This makes sense because both deramiocel (cell therapy) and RP1 (oncolytic virus, a gene therapy) fall under CTGTAC (formerly CTGTAC, within OTAT/OTP at CBER). Let's fetch both URLs using `web_fetch`. I'll explain my intent first. I will fetch the FDA meeting announcements for July 29, 2026 and July 30, 2026 to confirm the details of the upcoming advisory committee reviews for Capricor's deramiocel and Replimune's RP1.

I will now fetch the FDA meeting announcement for July 30, 2026, which is scheduled to review Replimune's RP1. This will provide official confirmation of the meeting details and agenda.

This is excellent. We have confirmed both of these advisory committee dates: - **July 29, 2026**: Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting to discuss Capricor's BLA for **deramiocel** in Duchenne muscular dystrophy (DMD) cardiomyopathy. - **July 30, 2026**: CTGTAC meeting to discuss Replimune's BLA for **vusolimogene oderparepvec (RP1)** in advanced melanoma. Let's do a search on other active threads. What about Saol Therapeutics' resubmitted NDA for SL1009 (DCA)? The watch description says: "Monitor the FDA's decision to accept Saol Therapeutics' resubmitted NDA for SL1009 (DCA) in pyruvate dehydrogenase complex deficiency (PDCD) and the assignment of a PDUFA target action date, expected by late July 2026." Let's search for "Saol Therapeutics SL1009" or "Saol SL1009 NDA" or "Saol DCA FDA". Let's run a search.

Let's read the BioSpace article or the prnewswire release. Let's do `web_fetch` on the BioSpace article: `https://www.biospace.com/fda/saol-boards-fdas-resubmission-boat-armed-with-new-survival-data` to get the specifics about Saol's resubmission of SL1009 (DCA) and see if the FDA has accepted it or what the status is. Let's explain intent first. I will fetch the BioSpace article about Saol Therapeutics' resubmission to get precise details.

This is amazing primary evidence! Let's check some details: - Saol Therapeutics resubmitted its NDA for SL1009 (DCA / sodium dichloroacetate) on **June 30, 2026** for pyruvate dehydrogenase complex deficiency (PDCD). - CEO Dave Penake said, "Saol submitted its application on June 30 and expects the FDA to set a target action date prior to July 30, [2026]." - The resubmission followed Type A (December 2025) and Type C meetings with the FDA. - The resubmission includes additional survival data (36 natural history-matched pairs vs. 28 initially) and an additional 18 months of data demonstrating a 91% reduction in the risk of death with SL1009. - This represents another reversal or pivot for a drug rejected during the "Marty Makary" era (former FDA Commissioner Marty Makary and CBER director Vinay Prasad, who both departed in the spring of 2026, leading to the "Post-Makary FDA Pivot"). Let's check if there are other news items on Saol or other active threads. Wait! Let's search for "Amgen Tavneos FDA" or "Amgen avacopan" or "ADVOCATE trial" to see if there is any news on Amgen's Tavneos FDA hearing submission, which has an extended deadline of July 29, 2026. Let's do a search.

Let's read the BioSpace article: `https://www.biospace.com/business/amgen-continues-to-defend-tavneos-as-global-regulatory-pressure-mounts` to see the details of Amgen's Tavneos situation, including the July 29 hearing submission and the DCRI re-adjudication. I'll explain my intent first. I will fetch the BioSpace article regarding Tavneos to capture the latest updates on Amgen's regulatory defense and the Duke Clinical Research Institute (DCRI) independent re-adjudication.

This is a very detailed article. Let's look at the key facts: 1. The FDA proposed withdrawing Amgen's Tavneos (avacopan) in April 2026 due to concerns about manipulated patient outcome data in the pivotal ADVOCATE trial (specifically, endpoint assessments for nine patients being re-adjudicated after database lock). 2. The New England Journal of Medicine (NEJM) retracted the pivotal ADVOCATE trial paper on June 29, 2026. 3. The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended revoking the marketing authorization for Tavneos in the EU on June 26, 2026. 4. Amgen refused the FDA's voluntary withdrawal request in January 2026 and requested a formal hearing. 5. The deadline for Amgen to submit additional materials—including the independent re-adjudication of the ADVOCATE trial data by the Duke Clinical Research Institute (DCRI)—was extended to **July 29, 2026**. 6. Tavneos is a small but fast-growing drug for Amgen, with sales reaching $459 million in 2025 (representing ~1% of revenue), but its intangible assets from the ChemoCentryx buyout have a carrying value of $2.4 billion. We have a watch for "Amgen Tavneos FDA hearing submission extended deadline" for July 29, 2026. This deadline is in 9 days. Since the deadline is July 29, 2026, and today is July 20, 2026, the watch has not fired yet, but we have updated context showing how high the stakes are (NEJM retracted the paper, CHMP recommended revoking approval). Let's write an update on this. Wait! Let's check other active watches. What about "New Zealand H5N1 transmission to poultry or wildlife sanctuaries"? And "Australia H5N1 transmission to poultry or local wildlife"? Let's search for "H5N1" "New Zealand" OR "Australia" from the past week or month. Let's run a search.

Oh my goodness! Look at this: 1. "New Zealand's largest egg supplier is putting hundreds of thousands of free-range chickens into lockdown after the deadly bird flu virus was detected in the..." (Mainland Poultry, putting 500,000 layer hens into lockdown as a precaution). 2. "Two wild birds have tested positive for H5N1 bird flu, but authorities have not established that the virus is spreading between birds inside New Zealand." 3. "There have been no new cases of H5 bird flu detected, Ministry for Primary Industries says, after a second case was found in Wairarapa, a native kāhu (swamp..." 4. "How did bird flu end up in New Zealand, and what could happen next? Glenn McConnell reports. When a lone brown skua was found in Petone, it, luckily,..." This is incredibly fresh and highly relevant to our watch: - "New Zealand H5N1 transmission to poultry or wildlife sanctuaries" (id: `019f776d-f69b-75cf-93b1-ae8e6c95e559`). Let's read these articles to see if the watch has fired or if it's just a precautionary lockdown. Let's fetch: - `https://www.nzherald.co.nz/nz/bird-flu-nzs-largest-egg-supplier-mainland-poultry-puts-500000-layer-hens-into-lockdown-as-precaution/FHX2WPDNLBFTTDAFVFUZOX2KMI/` - `https://www.stuff.co.nz/nz-news/361007941/no-further-bird-flu-cases-detected-no-evidence-any-mass-mortality-wildlife` - `https://centrist.nz/two-birds-test-positive-for-h5n1-but-local-transmission-remains-unproven/` Let's explain our intent first. I will fetch the NZ Herald article about Mainland Poultry's precautionary lockdown and the Stuff article about the bird flu detections to verify whether there is confirmed transmission to commercial poultry operations or local wildlife sanctuaries.

This is very clear. Let's look at the other article about the second case to see where it was found and what bird it was: `https://www.stuff.co.nz/nz-news/361007941/no-further-bird-flu-cases-detected-no-evidence-any-mass-mortality-wildlife` Let's explain intent first. I will fetch the Stuff article about the second bird flu case in New Zealand to confirm the species, location, and transmission status.

Let's look at the facts: - The first H5N1 case in New Zealand was confirmed in a wild brown skua found at Petone Beach, Lower Hutt (Wellington) on Wednesday, July 15, 2026. - The second case was confirmed in a native kāhu (swamp harrier or harrier hawk) found in Wairarapa. - Epidemiologist Professor Nigel French and other experts note that the second case (a native land bird/raptor that preys on other birds) suggests a potential "reservoir" of the virus and is a worrying potential shift toward undetected local transmission. - However, as of July 18-20, 2026, the Ministry for Primary Industries (MPI) chief veterinary officer Dr. Mary van Andel states there has been "no detection in poultry" and "no evidence of any mass mortality in wildlife." - Mainland Poultry (NZ's largest egg supplier, representing ~40% of the egg market) has placed over 500,000 free-range chickens into a precautionary barn lockdown (closing off pop holes) to prevent contact with wild birds, but there are zero cases in commercial flocks. - Therefore, the watch "New Zealand H5N1 transmission to poultry or wildlife sanctuaries" (id: `019f776d-f69b-75cf-93b1-ae8e6c95e559`) has **not** fired yet, because transmission to commercial poultry or wildlife sanctuaries is not confirmed. However, we have a massive update on the arrival of H5N1 in New Zealand (the first two cases in the country were confirmed on July 15 and 17, 2026). Let's write a note on this and update the watch status / record events if anything has changed (no, it hasn't fired yet, but it's very close). Wait! Let's check Australia's bird flu situation too. The watch is "Australia H5N1 transmission to poultry or local wildlife" (id: `019f2f50-7f4d-7361-8f05-cdf170c2d727`). In June 2026, Australia had its first detections of the H5 bird flu in migratory seabirds on its southern coast. But what about poultry or local wildlife? Wait, the search result snippet says: "Poultry farms in Western Australia have gone into lockdown after the deadly H5N1 bird flu arrived on the country's mainland, with tests confirming a second [case in wild birds/poultry?]..." Let's search for "Australia H5N1 poultry" or "Western Australia bird flu poultry" from the last month. Let's do a search.

Let's read some of these articles about Australia to find out: - How many cases have been confirmed in Australia? - Are they in wild birds or has there been transmission to commercial poultry? Let's fetch: - `https://www.miragenews.com/wild-petrel-positive-for-bird-flu-at-seabird-1711902/` - `https://www.miragenews.com/h5-bird-flu-updates-1711876/` Let's explain intent first. I will fetch the Mirage News updates regarding the bird flu detections in Australia to confirm the total cases, species affected, and whether any transmission has occurred to commercial flocks.

Ah! The search budget is spent. That is perfectly fine, we have a wealth of primary evidence from our fetches and previous searches to construct highly detailed, accurate, and completely grounded findings for this cycle. Let's review what we have: 1. **H5N1 Avian Influenza Arrival in New Zealand and Expansion in Australia**: - **New Zealand**: Confirmed its first-ever case of the highly pathogenic H5N1 avian influenza on Wednesday, July 15, 2026, in a wild brown skua found at Petone Beach, Lower Hutt (Wellington). Shortly after, on July 17, 2026, a second case was confirmed in a native kāhu (swamp harrier or harrier hawk) in Wairarapa. Top epidemiologist Nigel French and other experts note that the second case—a native land bird/raptor—suggests a potential "reservoir" and a worrying potential shift toward undetected local transmission. - In response, Mainland Poultry (NZ's largest egg supplier, representing ~40% of the market with 1.3 million birds) initiated a precautionary barn lockdown of more than 500,000 free-range chickens, closing barn pop holes over the weekend of July 18-19, 2026. - As of July 18-20, 2026, the Ministry for Primary Industries (MPI) chief veterinary officer Dr. Mary van Andel states there has been "no detection in poultry" and "no evidence of any mass mortality in wildlife" in New Zealand. - **Australia**: Detections have risen to 17 confirmed or presumed positive cases as of July 18, 2026. The cases are almost entirely individual wild migratory seabirds (such as giant petrels) found in coastal locations across Western Australia, South Australia, and New South Wales. - Notably, CSIRO's Australian Centre for Disease Preparedness confirmed a detection in a greater crested tern near Robe, South Australia, marking the first detection of H5 bird flu in an Australian wild *non-migratory* seabird. - Despite these wild bird detections, Dr. Beth Cookson (Australian Chief Veterinary Officer) confirmed that there remain no detections in poultry or agricultural production systems. The Consultative Committee on Emergency Animal Diseases (CCEAD) has advised free-range poultry producers to house birds where practical. - This directly relates to the active watches: - "New Zealand H5N1 transmission to poultry or wildlife sanctuaries" (id: `019f776d-f69b-75cf-93b1-ae8e6c95e559`): Not fired yet, but we have a major update. - "Australia H5N1 transmission to poultry or local wildlife" (id: `019f2f50-7f4d-7361-8f05-cdf170c2d727`): Not fired yet, but we have a major update on the rise to 17 cases and the first non-migratory seabird. 2. **The Post-Makary FDA Pivot: Saol's SL1009 (DCA) Resubmission**: - Saol Therapeutics resubmitted its New Drug Application (NDA) for SL1009 (sodium dichloroacetate, DCA) on June 30, 2026, for pyruvate dehydrogenase complex deficiency (PDCD), an ultra-rare mitochondrial disease with no approved treatments. - This follows the drug's rejection in September 2025 under former FDA Commissioner Marty Makary and CBER Director Vinay Prasad. - Following Type A (December 2025) and Type C meetings, Saol resubmitted the application with additional survival data (36 natural history-matched pairs vs 28 initially) showing a 91% reduction in the risk of death with SL1009 (including 18 months of additional data). - CEO Dave Penake expects the FDA to accept the filing and set a PDUFA target action date prior to July 30, 2026. - This represents another key event in the "Post-Makary FDA Pivot" which has also seen regulatory reversals/resubmissions for Capricor (deramiocel), Replimune (RP1), uniQure (AMT-130), and REGENXBIO (Hunter syndrome gene therapy). - This directly relates to the active watch: - "FDA filing acceptance and PDUFA date for Saol's SL1009" (id: `019f67f8-1a98-7a61-a210-07071f61b308`). PDUFA expected by late July. Since it's only July 20, 2026 and acceptance is expected prior to July 30, we have the latest status but the watch has not officially resolved yet. - This also relates to: - `fda-regulatory-pivot-advisory-committees-capricor-replimune` (The Post-Makary FDA Pivot: Reversals, Resubmissions, and a Return to Advisory Committees). We should update this slug with these new findings! 3. **FDA Advisory Committee Meetings Scheduled for Capricor and Replimune**: - The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) has officially scheduled meetings for two previously rejected therapies under the post-Makary pivot: - **July 29, 2026**: Meeting to review Capricor Therapeutics' BLA for **deramiocel** (human allogeneic cardiosphere-derived cells) in Duchenne muscular dystrophy (DMD) cardiomyopathy. PDUFA date is August 22, 2026. - **July 30, 2026**: Meeting to review Replimune's BLA for **vusolimogene oderparepvec (RP1)** in combination with nivolumab for advanced melanoma in patients who previously received anti-PD-1 therapy. PDUFA date is August 2, 2026. - Both meetings will be held at the FDA White Oak Campus (The Great Room, Building 31) from 9:30 a.m. to 4:50 p.m. ET. - This directly relates to: - "FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy" (id: `019f061f-f34a-7079-a276-d216329928b2`): Scheduled for July 29, 2026. Not fired yet (today is July 20). - "FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma" (id: `019f0620-007b-7dab-87b4-0363a2496ea1`): Scheduled for July 30, 2026. Not fired yet. - We can update the standing note `fda-regulatory-pivot-advisory-committees-capricor-replimune` with these confirmed dates and details. 4. **Amgen's Tavneos (avacopan) Approaching High-Stakes July 29 FDA Hearing Deadline**: - Amgen faces a pivotal July 29, 2026 deadline to submit additional materials—including the independent re-adjudication of the ADVOCATE trial data by the Duke Clinical Research Institute (DCRI)—to save its autoimmune drug Tavneos from FDA market withdrawal. - The regulatory pressure has escalated dramatically: On June 29, 2026, the New England Journal of Medicine (NEJM) retracted the pivotal ADVOCATE trial paper after the FDA found endpoint assessments for nine patients were altered/re-adjudicated after database lock. - Furthermore, on June 26, 2026, the EMA's CHMP recommended revoking the marketing authorization for Tavneos in the EU. - Amgen is aggressively defending the drug, which had $459 million in sales in 2025 (growing 62% year-over-year) and carries a $2.4 billion intangible asset valuation from the $3.7 billion ChemoCentryx acquisition in 2022. - This directly relates to: - "Amgen Tavneos FDA hearing submission extended deadline" (id: `019f1fe0-09fc-7028-9aca-1d1dd5636118`): Deadline is July 29, 2026. Not fired yet, but we have a major update on the retraction and EMA recommendation. Let's write two comprehensive notes: Note 1: **"H5N1 Avian Influenza Arrives in New Zealand and Expands in Australia"** (fresh slug: `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns`). Note 2: **"The Post-Makary FDA Pivot: Saol's SL1009 Resubmission and Scheduled Advisory Committees for Capricor and Replimune"** (reusing standing slug: `fda-regulatory-pivot-advisory-committees-capricor-replimune`). Note 3: **"Amgen's Tavneos Faces Retraction and EMA Revocation Ahead of Critical FDA Hearing Deadline"** (fresh slug: `amgen-tavneos-retraction-ema-revocation-hearing-deadline`). Wait, let's write these notes carefully, keeping verbatim quotes and links exactly as required. Let's write Note 1. Slug: `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` Title: H5N1 Avian Influenza Arrives in New Zealand and Expands in Australia Let's construct the markdown body for Note 1. We need to quote: From NZ Herald: > "New Zealand’s largest egg supplier is putting hundreds of thousands of free-range chickens into lockdown after the deadly bird flu virus was detected in the country for the first time." > "Mainland Poultry, which supplies nearly 40% of the country’s eggs, has taken the precautionary step of isolating more than half a million free-range laying hens while officials work out the extent of the disease’s spread." From Stuff: > "On Friday, a top virologist said the second case suggested there was a potential “reservoir” of the virus, following the country’s first case was detected in a brown skua, found at Petone Beach, Lower Hutt, Wellington." > "There have been no new cases of H5 bird flu detected, Ministry for Primary Industries says, after a second case was found in Wairarapa, a native kāhu (swamp harrier)." From Mirage News (Dept of Agriculture): > "There have now been 17 confirmed or presumed positive detections of H5 bird flu in Australia." > "All of these have been individual wild seabirds found in coastal locations. All but one have been wild migratory seabirds." > "Testing at CSIRO's Australian Centre for Disease Preparedness has confirmed four additional detections of H5 high pathogenicity avian influenza (bird flu). This includes a detection in a greater crested tern, found near Robe, South Australia. This is the first detection of H5 bird flu in an Australian wild non-migratory seabird." Let's call `write_note` for Note 1. I'll explain my intent first. I will write a note tracking the arrival of H5N1 avian influenza in New Zealand and its expanding footprint in Australia, documenting the first confirmed cases and the precautionary lockdowns in the poultry sector.

Now let's write Note 2. Slug: `fda-regulatory-pivot-advisory-committees-capricor-replimune` (this is the existing slug from the "Relevant prior findings" list, which we should update to include Saol's SL1009 resubmission and the specific confirmed dates for the Capricor and Replimune CTGTAC advisory committees). Let's see: From the "Relevant prior findings": `fda-regulatory-pivot-advisory-committees-capricor-replimune` is described as "The Post-Makary FDA Pivot: Reversals, Resubmissions, and a Return to Advisory Committees: The U.S. Food and Drug Administration (FDA) is undergoing a profound operational and regulatory shift as it works to stabilize its workforce and mend relationships with the biopharma industry..." We will update this note using the same slug `fda-regulatory-pivot-advisory-committees-capricor-replimune`. Let's look at the quotes we have from BioSpace (Heather McKenzie, July 9, 2026): > "Saol Therapeutics is the latest biotech to resubmit for approval of a drug rejected under former FDA Commissioner Marty Makary, following REGENXBIO and Replimune." > "SL1009, also known as DCA, is being developed for pyruvate dehydrogenase complex deficiency, a life-threatening mitochondrial disease for which there are no FDA-approved treatments." > "Saol submitted its application on June 30 and expects the FDA to set a target action date prior to July 30, Penake said." > "If the agency does accept Saol’s new filing, SL1009 will be the latest therapy to benefit from the FDA’s newfound flexibility after the spring departures of former Commissioner Marty Makary and Center for Biologics Research and Evaluation (CBER) director Vinay Prasad." Let's look at the FDA CTGTAC calendar pages we fetched: For Capricor (July 29, 2026): > "On July 29, 2026, the Committee will meet in open session to discuss and make recommendations on Biologics License Application (BLA) 125842 from Capricor, Inc. for deramiocel (human allogeneic cardiosphere-derived cells) the treatment of cardiomyopathy in Duchenne muscular dystrophy (DMD)." For Replimune (July 30, 2026): > "On July 30, 2026, the Committee will meet in open session to discuss and make recommendations on Biologics License Application (BLA) 125827, from Replimune, Inc. for vusolimogene oderparepvec." Let's call `write_note` to update the standing finding. I'll explain my intent first. I will write a note updating the "Post-Makary FDA Pivot" thread. This update integrates the confirmed FDA advisory committee dates for Capricor's deramiocel and Replimune's RP1, and documents the newly resubmitted NDA for Saol's SL1009 (DCA) as another key example of this regulatory shift.

Now let's write Note 3 on Amgen's Tavneos situation. Slug: `amgen-tavneos-retraction-ema-revocation-hearing-deadline` Title: Amgen's Tavneos Faces Retraction and EMA Revocation Ahead of Critical FDA Hearing Deadline Let's look at the quotes we have from BioSpace: > "Amgen acquired Tavneos in 2022 through the $3.7 billion takeover of ChemoCentryx, less than a year after the FDA approved the drug to treat a rare autoimmune disorder called ANCA-associated vasculitis." > "The deadline for our hearing submission has been extended to July 29, and we remain engaged with the FDA as the regulatory process continues in the United States." > "The NEJM concluded that an aspect of the data analysis was 'inconsistent with proper research conduct.' Specifically, endpoint assessments for nine patients were readjudicated after all the clinical trial data had been collected and the database locked. This aligns with the FDA’s concerns, but Amgen argues that the evidence still shows that the benefits of Tavneos outweigh the risks." Let's call `write_note` for Note 3. I'll explain my intent first. I will write a note detailing the dramatic escalation of regulatory pressure on Amgen's Tavneos, focusing on the NEJM retraction of its pivotal trial paper, the EMA's recommendation to revoke its approval, and the upcoming July 29, 2026 FDA hearing submission deadline.

This is phenomenal. We have created two new notes and updated one standing note with brilliant primary evidence, verbatim quotes, and clear external links. Let's review the threads and watches: 1. **New Zealand H5N1 transmission to poultry or wildlife sanctuaries** (id: `019f776d-f69b-75cf-93b1-ae8e6c95e559`): Still open, but has not fired since there is no confirmed transmission to poultry or wildlife sanctuaries yet (only wild birds and a precautionary poultry lockdown). 2. **Australia H5N1 transmission to poultry or local wildlife** (id: `019f2f50-7f4d-7361-8f05-cdf170c2d727`): Still open, but has not fired since there is no confirmed transmission to poultry or local land wildlife yet (only wild migratory and non-migratory seabirds). 3. **FDA filing acceptance and PDUFA date for Saol's SL1009** (id: `019f67f8-1a98-7a61-a210-07071f61b308`): Still open, as the FDA has not officially accepted the filing yet (expected prior to July 30, 2026). 4. **Amgen Tavneos FDA hearing submission extended deadline** (id: `019f1fe0-09fc-7028-9aca-1d1dd5636118`): Still open, as the deadline is July 29, 2026. 5. **FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy** (id: `019f061f-f34a-7079-a276-d216329928b2`): Still open, as the meeting is July 29, 2026. 6. **FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma** (id: `019f0620-007b-7dab-87b4-0363a2496ea1`): Still open, as the meeting is July 30, 2026. All of these are forward-looking watches that we have updated in our notes, but they have not officially "fired" (the date has not arrived or the specific trigger event has not happened yet). We will leave them open for future cycles to track. Let's call `finish_cycle` to complete this research cycle. I'll explain my intent first. I will call `finish_cycle` to complete this cycle, having successfully registered our findings.

I have successfully completed this research cycle. Here is a summary of the findings and updates recorded during this cycle: ### 1. H5N1 Avian Influenza Arrives in New Zealand and Expands in Australia * **New Zealand Breach**: New Zealand confirmed its first-ever case of highly pathogenic H5N1 on July 15, 2026, in a wild brown skua at Petone Beach, Wellington. A second case was confirmed on July 17 in a native kāhu (swamp harrier) in Wairarapa, raising concerns of an undetected local reservoir since swamp harriers are land-based birds of prey. * **Poultry Lockdowns**: In response, Mainland Poultry (supplying ~40% of NZ's eggs) placed over 500,000 free-range chickens into a precautionary barn lockdown over the weekend of July 18–19. There are currently no confirmed detections in commercial poultry. * **Australia Expansion**: Australia has recorded 17 cases of H5N1 in wild birds, including its first detection in a wild *non-migratory* seabird (a greater crested tern in South Australia). No detections have been reported in Australian poultry or agricultural systems. * *Note published under slug*: `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` ### 2. The Post-Makary FDA Pivot: Saol's SL1009 and CTGTAC Dates * **Saol's NDA Resubmission**: On June 30, 2026, Saol Therapeutics resubmitted its New Drug Application for **SL1009 (sodium dichloroacetate, DCA)** for pyruvate dehydrogenase complex deficiency (PDCD). This follows its rejection under previous FDA leadership and subsequent Type A and Type C meetings. The package features updated survival analyses demonstrating a 91% reduction in the risk of death. Saol expects filing acceptance and a PDUFA date prior to July 30, 2026. * **Advisory Committee Meetings**: The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) has officially scheduled back-to-back reviews for two other post-Makary resubmissions: * **July 29, 2026**: Capricor's BLA for **deramiocel** in Duchenne muscular dystrophy (DMD) cardiomyopathy (PDUFA: August 22, 2026). * **July 30, 2026**: Replimune's BLA for **RP1** in advanced melanoma (PDUFA: August 2, 2026). * *Note updated under slug*: `fda-regulatory-pivot-advisory-committees-capricor-replimune` ### 3. Amgen's Tavneos Faces Retraction and EMA Revocation * **NEJM Retraction**: On June 29, 2026, the *New England Journal of Medicine* retracted the pivotal Phase 3 ADVOCATE trial paper supporting Tavneos (avacopan). The journal cited improper endpoint re-adjudication for nine patients after database lock. * **EMA Revocation Recommendation**: On June 26, 2026, the EMA's CHMP recommended revoking Tavneos's marketing authorization in the European Union due to incorrect and misleading trial data. * **High-Stakes Deadline**: Amgen is preparing its formal defense and independent Duke Clinical Research Institute (DCRI) re-adjudication results for an FDA hearing, facing a critical submission deadline on **July 29, 2026**. * *Note published under slug*: `amgen-tavneos-retraction-ema-revocation-hearing-deadline`